Literature DB >> 590598

The interactions of ticlopidine and aspirin in normal subjects.

J J Thebault, C E Blatrix, J F Blanchard, E A Panak.   

Abstract

This trial was performed on 24 health volunteers in order to study the possible interactions between aspirin and ticlopidine. The results confirm the inhibitory activity of aspirin on collagen-induced aggregation and that of ticlopidine on ADP-induced aggregation. If aspirin does not modify the inhibitory effect of ticlopidine on ADP-induced aggregation, ticlopidine on the other hand potentiates the effect of aspirin on collagen-induced aggregation.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 590598     DOI: 10.1177/030006057300100204

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  5 in total

1.  Pharmacokinetics and pharmacodynamics of sibrafiban alone or in combination with ticlopidine and aspirin.

Authors:  B Wittke; H Ensor; J Chung; H Birnböck; B Lausecker; S I Ertel; I J MacKie; S J Machin
Journal:  Br J Clin Pharmacol       Date:  2000-03       Impact factor: 4.335

Review 2.  Ticlopidine. An updated review of its pharmacology and therapeutic use in platelet-dependent disorders.

Authors:  D McTavish; D Faulds; K L Goa
Journal:  Drugs       Date:  1990-08       Impact factor: 9.546

Review 3.  Ticlopidine. A review of its pharmacology, clinical efficacy and tolerability in the prevention of cerebral ischaemia and stroke.

Authors:  S Noble; K L Goa
Journal:  Drugs Aging       Date:  1996-03       Impact factor: 3.923

4.  Life-threatening subcutaneous hemorrhage following minor blunt trauma in an elderly patient taking ticlopidine and aspirin: a case report.

Authors:  Akiyoshi Hagiwara; Takeaki Matsuda; Shuji Shimazaki
Journal:  Emerg Radiol       Date:  2005-11-26

Review 5.  Ticlopidine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states.

Authors:  E Saltiel; A Ward
Journal:  Drugs       Date:  1987-08       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.